Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naftopidil - Asahi Kasei Pharma

Drug Profile

Naftopidil - Asahi Kasei Pharma

Alternative Names: Avishot; BM-15275; Eapidil; Flivas; KT-611; Naphtopidil

Latest Information Update: 11 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Asahi Kasei; Asahi Kasei Pharma Corp; Dong-A ST; MSD KK
  • Class Antihypertensives; Naphthalenes; Piperazines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia
  • Phase III Postoperative pain
  • No development reported Neurogenic bladder; Urinary calculi

Most Recent Events

  • 19 Jan 2018 No development reported - Phase-III for Urinary calculi in South Korea (PO)
  • 01 Aug 2015 Dong-A ST completes a phase III trial in Urinary calculi in South Korea (NCT01952314)
  • 01 May 2014 Phase-III clinical trials in Urinary calculi in South Korea (PO) (NCT01952314)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top